# LAPIS

Source: https://onco.cc/trials/lapis-trial/  
OnCo record `lapis-trial` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The anti-stroma antibody pamrevlumab did not help people with locally advanced pancreatic cancer live longer.

## Summary

LAPIS randomised patients with locally advanced, unresectable pancreatic ductal adenocarcinoma to pamrevlumab or placebo with either gemcitabine plus nab-paclitaxel or FOLFIRINOX, with the aim of increasing resection and survival. FibroGen reported in 2024 that the trial did not meet its primary overall survival endpoint.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-17
- Registry id: NCT03941093
- Phase: 3
- Setting: Locally advanced unresectable pancreatic cancer: pamrevlumab with gemcitabine and nab-paclitaxel or FOLFIRINOX versus chemotherapy alone
- Sponsor: FibroGen
- Result: Primary overall survival endpoint not met.

## Sources

- ClinicalTrials.gov NCT03941093: https://clinicaltrials.gov/study/NCT03941093

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [Pamrevlumab](https://onco.cc/drugs/pamrevlumab/)

---
JSON: https://onco.cc/api/v1/entities/lapis-trial.json